Tuesday, June 3, 2025
The Lagos Today
  • Login
No Result
View All Result
No Result
View All Result
The Lagos Today
No Result
View All Result
Home Biotech

Neurocrine and Idorsia End Partnership Following Phase 2 Trial Failures of Epilepsy Drug

by Iyanu Ale
October 29, 2024
in Biotech
Reading Time: 2 mins read
0
0
Neurocrine and Idorsia End Partnership Following Phase 2 Trial Failures of Epilepsy Drug
Share on FacebookShare on Twitter

After two years and multiple unsuccessful trials, Neurocrine Biosciences and Swiss biotech Idorsia have officially ended their collaboration on NBI-827104, a calcium channel blocker initially aimed at treating epilepsy. The partnership, which began with high hopes in 2019, faced a rocky path after the drug candidate failed to meet key benchmarks in two phase 2 trials.

Idorsia initially developed NBI-827104, banking on its ability to penetrate the brain and block calcium channels thought to play a role in epilepsy. In 2019, Neurocrine joined the effort, paying an initial $5 million to collaborate, followed by a $45 million investment to advance the program further.

However, the promise of the drug began to fade after NBI-827104 missed its primary endpoint in a phase 2 trial for essential tremor, prompting Neurocrine to discontinue its tremor program. Later, in 2022, additional disappointment followed as the drug failed to outperform a placebo in another phase 2 trial targeting pediatric epileptic encephalopathy with continuous spike-and-wave during sleep—a severe epilepsy condition in children.

At the time, Neurocrine’s Chief Medical Officer, Dr. Eiry Roberts, expressed that the team would closely analyze the data to assess the potential future of the program. But the latest announcement in Idorsia’s third-quarter earnings call has confirmed that the companies, after further evaluation of open-label extension data, have decided to terminate any further development of NBI-827104, also known as ACT-709478.

“With this decision, the development agreement has officially come to an end,” Idorsia shared in its statement. The conclusion of this collaboration underscores the high stakes and challenges in developing breakthrough therapies in the field of neurology.

Share this:

  • Facebook
  • X

Like this:

Like Loading...
Tags: EpilepsyIdorsiaNeurocrine
Previous Post

Novartis Faces Setback with MorphoSys Acquisition as Safety Concerns Delay Key Drug Approval Plans

Next Post

GSK Invests $300M in Next-Generation Lupus Drug from Chimagen Biosciences

Iyanu Ale

Iyanu Ale

Related Posts

Biotech Innovator Lykos Forges Ahead with Groundbreaking MDMA Treatment

by Iyanu Ale
January 17, 2025
0

Lykos, a biotech company, has been making headlines with its innovative approach to treating post-traumatic stress disorder (PTSD). The company's...

Biotech Breakthrough Verdiva Raises $410M to Revolutionize Obesity Treatment with Game-Changing Weight Loss Drug

Biotech Breakthrough Verdiva Raises $410M to Revolutionize Obesity Treatment with Game-Changing Weight Loss Drug

by Iyanu Ale
January 9, 2025
0

Verdiva, a biotechnology company, has burst onto the scene with a staggering $410 million Series A funding round. This monumental...

Next Post
GSK Invests $300M in Next-Generation Lupus Drug from Chimagen Biosciences

GSK Invests $300M in Next-Generation Lupus Drug from Chimagen Biosciences

Please login to join discussion

Recommended

5 Dead, Toddler Among 16 Injured In Ghastly Auto-crash Along Lagos-Ibadan Expressway

Two Die in Lagos-Abeokuta Expressway Accident

2 years ago
Catch Them Young: 450 School Students receive empowerment in Golf Training 

Catch Them Young: 450 School Students receive empowerment in Golf Training 

2 years ago

Popular News

    Connect with us

    Tags

    #EndSARS 2023 Elections 2023 polls 2023 Presidency ACCIDENT Africa All progressives Congress APC Asiwaju Bola Tinubu Babajide Sanwo-Olu CBN Central Bank of NIgeria Central Bank of Nigeria (CBN) Coronavirus pandemic Covid-19 Covid-19 in Lagos Covid-19 in Nigeria Covid-19 Vaccine Cryptocurrency Economic and Financial Crimes Commission EFCC Federal Government Federal Government of Nigeria Fraud Gov. Sanwo-Olu House of Representatives Lagos-Ibadan expressway Lagos state Lagos State Government Lagos State House of Assembly Lagos State Police command Muhammadu Buhari Murder Naira NDLEA Nigeria Nigeria Customs Service Nigerian Economy Nigeria Police Force Rape Strike action TECH UK United Kingdom US

    News

    Opinion

    © 2020 The Lagos Today - Nkali.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    No Result
    View All Result

    © 2020 The Lagos Today - Nkali.

    %d